Table 3.
Multivariate logistic regression model predicting use of PJP prophylaxis among patients with rheumatic conditions.
| Characteristic | Unadjusted OR (95% CI) |
Adjusted OR (95% CI) |
|---|---|---|
| Sex (Male vs. Female) | 1.61 (0.92,2.79) | 0.84 (0.43,1.64) |
| Age (per 1 year) | 1.01 (0.99,1.02) | 0.99 (0.98,1.01) |
| Race (Non-white vs. White) | 0.65 (0.41,1.03) | 1.12 (0.62,2.03) |
| Diagnosis | ||
| Granulomatosis with polyangiitis | 5.14 (2.59,10.19) | 5.74 (2.41,13.70) |
| Microscopic polyangiitis | 4.73 (1.84,12.15) | 6.59 (2.10,20.73) |
| Dermatomyositis | 3.49 (1.86, 6.56) | 5.04 (2.46,10.29) |
| Polymyositis | 1.59 (0.55,4.54) | 2.74 (0.87, 8.59) |
| SLE | referent | referent |
| Anchor immunosuppressant | ||
| Cyclophosphamide (CYC) | 12.16 (4.06,36.42) | 18.90 (5.77, 61.91) |
| Rituximab | 7.97 (3.05, 20.80) | 5.62 (1.99,15.93) |
| High-dose glucocorticoids (GC) | 2.40 (1.07, 5.41) | 2.57 (1.07,6.17) |
| Mycophenolate mofetil (MMF) | 0.99 (0.40, 2.44) | 1.14 (0.43,2.97) |
| Azathioprine (AZA) | 1.85 (0.68, 5.06) | 1.24 (0.41, 3.74) |
| Methotrexate (MTX) | referent | referent |
Model c-statistic = 0.789